Licence extension for Januvia

Januvia (sitagliptin) is now licensed for first-line treatment of type II diabetes when metformin is contraindicated or not tolerated. The recommended dose is 100mg once daily.

View Januvia drug record

Further information: Merck

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New shingles vaccine awaits decision on NHS use

New shingles vaccine awaits decision on NHS use

Shingrix, which is now available privately in the UK,...

Products coming soon - live tracker

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

New products - live tracker

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...